Novel Oral Anticoagulants, A Subject in Continuing Debate

1. Kristensen SD, Knuuti J, Saraste A et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol. 2014;31(10):517-73.10.1097/EJA.000000000000015025127426Search in Google Scholar

2. 2014 ESC/ESA Guidelines on non-cardiac surgery:cardiovascular assessmeny and management, European Heart Journal, 2014.Search in Google Scholar

3. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.10.1056/NEJMoa090556119717844Search in Google Scholar

4. Go AS, Singer DE, Toh S et al. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med. 2017;167(12):845-854.10.7326/M16-115729132153Search in Google Scholar

5. Connolly SJ, Wallentin L, Yusuf S. Additional events in the RE-LY trial. N Engl JMed. 2014;371(15):1464-5.10.1056/NEJMc140790825251519Search in Google Scholar

6. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl JMed. 2011;365(11):981-92.10.1056/NEJMoa110703921870978Search in Google Scholar

7. Alexander JH, Lopes RD, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl JMed. 2011;365(8):699-708.10.1056/NEJMoa110581921780946Search in Google Scholar

8. Korjian S, Braunwald E, Daaboul Y et al. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarkerpositive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. Eur Heart J Acute Cardiovasc Care. 2017:2048872617745003.10.1177/204887261774500329249166Search in Google Scholar

9. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.10.1056/NEJMoa100963821830957Search in Google Scholar

10. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104.10.1056/NEJMoa131090724251359Search in Google Scholar

11. Siegal DM, Curnutte JT, Connolly SJ et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl JMed. 2015;373(25):2413-24.10.1056/NEJMoa151099126559317Search in Google Scholar

12. Ansell JE, Bakhru SH, Laulicht BE et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141-2.10.1056/NEJMc1411800Search in Google Scholar

13. Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. AmJ Emerg Med. 2016;34(11S):26-32.10.1016/j.ajem.2016.09.050Search in Google Scholar

14. Choo WK, Fraser S, Padfield G et al. Dabigatran improves the efficiency of an elective direct current cardioversion service. Br J Cardiol 2014;21:29–32.Search in Google Scholar

15. Cappato R, Ezekowitz MD, Klein AL et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55.10.1093/eurheartj/ehu367Search in Google Scholar

16. Sakabe M, Yoshioka R, Fujiki A. Low APTT and BMI predicts the occurrence of ischemic stroke in patients with Atrial Fibrillation receiving Dabigatran, JACC 2014; 63(12):A1436.10.1016/S0735-1097(14)61436-4Search in Google Scholar

17. Burnett A, Siegal D, Crowther M. Specific antidotes for bleeding associated with direct oral anticoagulants. BMJ. 2017;357:j2216.10.1136/bmj.j221628546438Search in Google Scholar

18. Heidbuchel H, Verhamme P, Alings M, et al. Advisors. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2016;9:ehw058.10.1093/eurheartj/ehw058583723127282612Search in Google Scholar

19. Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016;41:206-32.10.1007/s11239-015-1310-7471584826780747Search in Google Scholar

20. Nafee T, Aslam A, Chi G et al. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors. Expert Rev Cardiovasc Ther. 2017;15(4):237-245.10.1080/14779072.2017.130588928282497Open DOISearch in Google Scholar

21. Burnett A, Siegal D, Crowther M. Specific antidotes for bleeding associated with direct oral anticoagulants. BMJ 2017;357:j221610.1136/bmj.j2216Search in Google Scholar